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Abstract
Human embryonic stem cells (hESCs) are self-renewing pluripotent cells that can differentiate into specialized cells
and hold great promise as models for human development and disease studies, cell-replacement therapies, drug
discovery and in vitro cytotoxicity tests. The culture and differentiation of these cells are both complex and expensive,
so it is essential to extreme aseptic conditions. hESCs are susceptible to Mycoplasma sp. infection, which is hard to
detect and alters stem cell-associated properties. The purpose of this work was to evaluate the efficacy and cytotoxic
effect of PlasmocinTM and ciprofloxacin (specific antibiotics used for Mycoplasma sp. eradication) on hESCs.
Mycoplasma sp. infected HUES-5 884 (H5 884, stable hESCs H5-brachyury promoter-GFP line) cells were
effectively cured with a 14 days PlasmocinTM 25 µg/ml treatment (curative treatment) while maintaining stemness
characteristic features. Furthermore, cured H5 884 cells exhibit the same karyotype as the parental H5 line and
expressed GFP, through up-regulation of brachyury promoter, at day 4 of differentiation onset. Moreover, H5 cells
treated with ciprofloxacin 10 µg/ml for 14 days (mimic of curative treatment) and H5 and WA09 (H9) hESCs treated
with PlasmocinTM 5 µg/ml (prophylactic treatment) for 5 passages retained hESCs features, as judged by the
expression of stemness-related genes (TRA1-60, TRA1-81, SSEA-4, Oct-4, Nanog) at mRNA and protein levels. In
addition, the presence of specific markers of the three germ layers (brachyury, Nkx2.5 and cTnT: mesoderm; AFP:
endoderm; nestin and Pax-6: ectoderm) was verified in in vitro differentiated antibiotic-treated hESCs. In conclusion,
we found that PlasmocinTM and ciprofloxacin do not affect hESCs stemness and pluripotency nor cell viability.
However, curative treatments slightly diminished cell growth rate. This cytotoxic effect was reversible as cells
regained normal growth rate upon antibiotic withdrawal.
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Introduction
Human embryonic stem cells (hESCs) are pluripotent cells
derived from the inner cell mass of early human embryos.
Under optimal in vitro culture conditions, these cells can self-
renew and be cultured indefinitely in an undifferentiated state
while maintaining stemness features. Moreover, they can
differentiate into virtually all adult cell type derived from the
three germ layers: ectoderm, mesoderm and endoderm
(pluripotency). Therefore, hESCs hold great promise as models
for human development and disease, as well as for drug
discovery and cell-replacement therapies. Particularly, due to
their reliance on many key pathways in morphogenesis and
differentiation, hESCs may find an immediate pharmacological
application for in vitro drug toxicity testing models [1–3].
hESCs in vitro culture maintenance and differentiation
protocols are very expensive and time consuming processes. It
is extremely important then, for both basic research and
biotechnological manufacture, to avoid or eventually eradicate
any type of microorganism contamination, like fungal or
bacterial infections, from hESCs cultures. In particular,
mycoplasmas are small microorganisms (0.3-0.8 µm) which
lack a rigid cell wall and belong to the class Mollicutes
(Mycoplasma sp. and Acholeplasma sp.) [4]. They are part of
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the physiological human flora as well as opportunistic
pathogens. Moreover, Mycoplasma sp. is one of the most
frequent contaminants found in eukaryotic cell cultures. In fact,
their infection frequency ranges from 5 to 35% of cell cultures,
depending upon the country and laboratory of origin [5,6], and
it may be as high as 65-80% in some cell culture facilities [7].
Mycoplasmas within individual cell cultures could reach titers of
108 colony forming units per milliliter [5]. Recent studies found
that Mycoplasma sp. is one of the most common
microbiological contaminants of stem cell cultures, as 4% (n=7)
out of 158 cell passages from 32 stem cell and feeder cell lines
were infected [8].
Mycoplasmas cannot be visualized under inverted
microscope and neither show turbidity of the culture medium
unlike other bacterial contamination. As a consequence,
mycoplasmal infection of cell cultures could often persist for
long periods of time without being noticed and with no apparent
cell damage [9]. However, contaminating mycoplasmas affect
virtually every parameter within the cell culture system. For
instance, alterations in growth characteristics, enzyme
patterns, cell membrane composition, chromosomal
abnormalities, and induction of cytopathogenic changes have
been described [10–12]. In what respects to stem cells, it was
demonstrated that Mycoplasma sp. contamination of murine
embryonic stem cells reduces growth rate and viability and
affects their pluripotent capacity [13].
The effectiveness in mycoplasmas eradication of several
antibiotics have been demonstrated in vitro [14–16]. Among
these antibiotics, some of the more commonly used are
PlasmocinTM and Ciprofloxacin. Both are well-established anti-
Mycoplasma sp. reagents that are used to cure contaminated
cell lines in as little as a two-week treatment (25 µg/ml
PlasmocinTM and 10 µg/ml Ciprofloxacin) [16–21]. Moreover,
PlasmocinTM was also used prophylactically to prevent
Mycoplasma sp. infection at a concentration of 5 µg/ml [22,23].
It is important to consider the possible toxic effects of
antibiotic treatments on stem cell culture, especially with
regards to cytotoxicity, loss of special cellular characteristics
and clonal selection. In this sense, it has been reported the
occurrence of cell culture loss as a result of cell death in up to
11% of the cell lines treated with anti-Mycoplasma sp.
antibiotics [14]. The effectiveness of anti-Mycoplasma sp.
antibiotics and their possible side effects have not been fully
studied yet on human pluripotent stem cells. Therefore, the aim
of this work is to study whether contaminated hESCs can be
cured with an anti-Mycoplasma sp. antibiotic treatment and,
even more important, if curative and also prophylactic
treatments affect maintenance of undifferentiated state, self-
renewal, pluripotency, viability and growth of hESCs.
In the present study we found that PlasmocinTM curative
treatment effectively eradicated Mycoplasma sp. contamination
from the hESCs line HUES-5 884 (H5 884). Importantly, in
cured H5 884 cells, stemness characteristics (cells morphology
and expression of specific markers), karyotype and pluripotent
capacity remained unaltered compared to HUES-5 (H5)
parental cell line. Moreover, neither maintenance of the
undifferentiated state nor pluripotent properties of hESCs lines
WA09 (H9) and H5 were affected upon PlasmocinTM and
Ciprofloxacin prophylactic and curative treatments,
respectively. However, even though anti-Mycoplasma sp.
antibiotics did not affect hESCs viability or apoptosis rate,
PlasmocinTM and Ciprofloxacin slowed down hESCs growth
rates when used at curative concentrations.
Materials and Methods
Reagents, cell lines and culture
Ciprofloxacin was purchased from Sigma (MO, USA) and
PlasmocinTM from Invivogen (CA, USA). The hESC line WA09
(H9) (46,XX karyotype) [1] was purchased from WiCell
Research Institute (WI), and the hESC line HUES-5 (H5)
[46,XX, inv(9) karyotype] [24] was acquired from Harvard
University and the Howard Hughes Medical Institute (MA). Both
cell lines are approved for US National Institute of Health (NIH)
funding. hESCs were maintained on inactivated mouse
embryonic fibroblast (iMEF) feeder layers in medium
DMEM/F12 supplemented with 10% KSR, 2 mM non-essential
amino acids, 2 mM L-glutamine, 100 U/ml penicillin, 50 µg/ml
streptomycin, 0.1 mM β-mercaptoethanol and 4 ng/ml of bFGF.
All these reagents were obtained from Invitrogen (CA, USA).
hESCs were transferred with 1mg/ml collagenase IV
(Invitrogen, CA, USA) into new iMEF feeder layers or into
feeder-free diluted (1/40) MatrigelTM (BD Bioscience, CA, USA)
coated dishes containing iMEF conditioned medium. For the
conditioning medium, 3x106 iMEF cells were incubated for 24h
with 25 ml of DMEM/F12 medium supplemented with 5% KSR
and 2 ng/ml of bFGF (in addition to the other aforementioned
supplements) and stored at -20°C. After thawing, KSR and
bFGF were added to a final concentration of 20% and 8 ng/ml,
respectively. For some experiments, hESCs grown on
MatrigelTM were dissociated into single cells using accutase 1x
(Invitrogen, CA, USA) for 20 minutes, plated onto MatrigelTM
coated dishes (with addition of 10µM Y-27632 ROCK inhibitor,
R&D Systems, MN, USA) and grown until confluence with
conditioning medium.
Human foreskin fibroblasts were prepared as primary
cultures from freshly obtained human foreskins as soon as
possible after surgery. The isolated fibroblasts were then
expanded, frozen and stored as described elsewhere. The
study was given ethical approval by the local Ethics Committee
(Comité de ética en investigaciones biomédicas del Instituto
FLENI) and written informed consent was obtained from donor
prior to fibroblast isolation.
HUES-5 (H5)-Brachyury-GFP stable hESC cell line
generation
The stable H5 cell line (H5 884) encoding GFP under the
control of a fragment of the Brachyury promoter was generated
as previously described [25].
Mycoplasma sp. detection
Briefly, cells were washed with PBS and then scraped into
10 ml medium. 1 ml of cell suspension was transferred into a
1.5 ml eppendorf tube and centrifuged at 10,000 x g for 10 min
at 4°C. Supernatant was discarded and pellet was suspended
Effect of Anti-Mycoplasma Antibiotics on hESCs
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in 100 µl lysis buffer [10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2
mM MgCl2, 0.001% gelatin, 0.5% NP-40, 0.5% Tween-20 and 1
µl of proteinase-K (10 mg/ml, Invitrogen, CA, USA)]. Cell
suspension was lysed at 60°C for 1 hour. Nucleic acid was
precipitated with 600 µl isopropanol, kept at -20°C for 30 min
and centrifuged for 30 min at 4°C. Pellet was washed with 70%
ethanol, air dried and re-suspended in 50 µl TE (10 mM Tris-
HCl-1 mM EDTA pH 8.0). DNA content was determined using a
NanoDrop 2000 Spectrophotometer (Thermo Scientific, MA,
USA). 100 ng of sample DNA and 1 ng of positive control
(genomic DNA from Mycoplasma orale) were used for PCR
amplification at an annealing temperature of 55°C. Primers
used were: MYCPL; sense, 5´-
ACACCATGGGAGYTGGTAAT-3´; antisense, 5´-
CTTCWTCGACTTYCAGACCCAAGGCAT-3´.
Embryoid bodies differentiation protocol
To induce differentiation, hESCs colonies were dispersed
with 1 mg/ml collagenase IV (Invitrogen, CA, USA) for 1 hour.
Cells were then transferred to non-adherent Petri dishes
containing DMEM supplemented with 20% fetal bovine serum
(Gibco, CA, USA), 2 mM L-glutamine, 100 U/ml penicillin and
50 µg/ml streptomycin used as differentiation medium. Cells
incubated in suspension at 37°C and 5% CO2 for 7 days
aggregated to form embryoid bodies (EBs), which were then
plated onto 0.1% gelatin coated 24-well plates and cultured for
additional 7 days. Normally, within 2-4 days after plating, tissue
like-structures including contractile areas and neural rosettes
were observed in the outgrowth of the EBs.
RNA isolation and RT-qPCR
Total RNA was extracted from hESCs with Trizol (Invitrogen,
CA, USA) and cDNA was synthesized from 500 ng of total RNA
with 15 mM of random hexamers (Invitrogen, CA, USA) and
MMLV reverse transcriptase (Promega, WI, USA), according to
manufacturer’s instructions. For real-time PCR studies, cDNA
samples were diluted 5-fold and PCR amplification and
analysis were performed with StepOnePlus Real Time PCR
System (PE Applied Biosystems, CA, USA). The SYBR®
GreenERTM qPCR SuperMix UDG (Invitrogen, CA, USA) was
used for all reactions, following manufacturer instructions.
Primers used were the following: RPL7; sense, 5´-
AATGGCGAGGATGGCAAG-3´; antisense, 5´-
TGACGAAGGCGAAGAAGC-3´; OCT-4; sense, 5´-
CTGGGTTGATCCTCGGACCT-3´; antisense, 5´-
CACAGAACTCATACGGCGGG-3´; NANOG; sense, 5´-
AAAGAATCTTCACCTATGCC-3´; antisense, 5´-
GAAGGAAGAGGAGAGACAGT-3´; PAX-6; sense, 5´-
CAGGTGTCCAACGGATGTG-3´; antisense, 5´-
GTCGCTACTCTCGGTTTACTAC-3´; BRACHYURY; sense, 5
´-TCCCAGGTGGCTTACAGATGA-3´; antisense, 5´-






hESCs were analyzed for in situ immunofluorescence.
Briefly, cells were rinsed with PBS and fixed in PBSA (PBS
with 0.1% bovine serum albumin) with 4% formaldehyde for 45
min. After two washes cells were permeabilized with 0.1%
Triton X-100 in PBSA with 10% normal goat serum for 30 min,
washed twice and stained with the corresponding primary
antibodies: murine monoclonal antibodies anti-SSEA4 (813-70)
(sc-21704), anti-Tra-1-60 (sc-21705), anti-Tra-1-81 (sc-21706),
anti-Oct-3/4 (C-10) (sc-5279), anti-Troponin T-C (CT3)
(sc-20025), anti-AFP (F8) (sc-166325) from Santa Cruz
Biotechnology (CA, USA); rabbit monoclonal antibody anti-
Nanog (D73G4) XP (R) from Cell Signaling Technology Inc.
(MA, USA) and rabbit polyclonal antibody anti-Nestin (AB5922)
from Millipore (MA, USA). Appropriate Alexa-conjugated
secondary antibodies were purchased from Invitrogen (CA,
USA) and used to localize the antigen/primary antibody
complexes. Cells were counterstained with 4,6-diamidino-2-
phenylindole (DAPI) (Invitrogen, CA, USA) and examined
under a Nikon Eclipse TE2000-S inverted microscope. Images
were acquired with a Nikon DXN1200F digital camera, which
was controlled by the EclipseNet software (version 1.20.0 build
61). Cell number was estimated using the ITCN ImageJ-plugin
software (Center for Bio-Image Informatics at University of
California, USA) (Wayne Rasband, National Institutes of
Health, USA. http://rsb.info.nih.gov/ij/).
Cell viability assay
For cell viability assays, 1x104 hESCs were plated onto
MatrigelTM coated 96-well plates and grown until confluence. 24
and 48h post antibiotics addition, 50 µg/well of activated 2,3-bis
(2-methoxy-4-nitro-5-sulfophenyl)-5 [(phenylamino)
carbonyl]-2-H-tetrazolium hydroxide (XTT) (Sigma, MO, USA)
in PBS containing 0.3 µg/well of the intermediate electron
carrier, N-methyl dibenzopyrazine methyl sulfate (PMS)
(Sigma, MO, USA) were added (final volume 100 µl) and
incubated for 2 h. Cellular metabolic activity was determined by
measuring the absorbance of the samples with a
spectrophotometer (Bio-Rad, CA, USA) at a wavelength of 450
nm and subtracting the background absorbance at 690 nm.
TUNEL assay
An in situ cell death detection kit using TdT-mediated
fluorescein-conjugated dUTP nick end labeling (TUNEL, In Situ
Cell Death Detection Kit Fluorescein, AP; Roche Molecular
Biochemicals, Mannheim, Germany) was used to detect
apoptotic cells following manufacturer’s instructions. The
procedure, using a photometric enzyme immunoassay,
determines cytoplasmic histone-associated DNA fragments
(mono- and oligonucleosomes) after cell death. Fluorescein
labels were detected by fluorescence and examined under a
Nikon Eclipse TE2000-S inverted microscope equipped with a
20X E-Plan objective and a super high-pressure mercury lamp.
The images were acquired with a Nikon DXN1200F digital
camera, which was controlled by the EclipseNet software
(version 1.20.0 build 61). Cell number was estimated using the
ITCN ImageJ-plugin software (Center for Bio-Image Informatics
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at University of California, USA) (Wayne Rasband, National
Institutes of Health, USA. http://rsb.info.nih.gov/ij/).
Alkaline Phosphatase assay
H9 hESCs were plated as small clumps onto iMEF feeder
cells in 6-well plates. After 7 days antibiotics treatment, cells
were washed with PBS and subjected to alkaline phosphatase
staining following manufacturer’s instructions (Sigma, MO,
USA).
In-Cell Western assay
The assay was performed as per manufacturer instructions
(Licor Bioscience, Lincoln, NE, USA). For cell growth
experiments, small clumps of H9 were plated onto iMEF feeder
layers 24-well plates and treated for 7 days. For cell growth
recovery experiments, antibiotics were withdrawn after curative
treatments, cells passaged twice and then same number of
small clumps were plated onto iMEF feeder layers 24-well
plates and cultured for 7 days. Cells were then rinsed with PBS
and fixed in PBSA (PBS with 0.1% bovine serum albumin) with
4% formaldehyde for 45 min. After two washes cells were
permeabilized with 0.1% Triton X-100 in PBSA with 10%
normal goat serum for 30 min, washed twice and incubated
overnight at 4°C with the corresponding primary antibodies:
murine monoclonal antibody anti-Oct-3/4 (C-10) (sc-5279)
1:200 from Santa Cruz Biotechnology (CA, USA) and rabbit
monoclonal antibody anti-Nanog (D73G4) XP (R) 1:400 from
Cell Signaling Technology Inc. (MA, USA). After primary
antibody incubations, plates were washed thrice with PBSA.
Then, secondary antibodies from Licor Biosciences (NE, USA)
conjugated to IRDye 800CW (goat-anti-mouse-IgG) 1:1,000
and to IRDye 680 (goat-anti-rabbit-IgG) 1:200 were used.
Plates were incubated with secondary antibodies solutions for
60 minutes at room temperature in the dark. Background
control wells were prepared by omitting primary antibodies (i.e.,
secondary only). After secondary antibody incubations, plates
were washed thrice with PBSA the dark, and then plates were
air-dried before scanning. Plates were scanned and analyzed
using an Odyssey Infrared Imaging Scanner and Odyssey
imaging software 3.0. Scan settings used were medium image
quality, 169 µm resolution, intensity 5.0 for the both the 700-
channel and 800-channel with an offset of 3.0 mm. For signal
quantification, antibody signals were analyzed as the average
700 and 800-channel integrated intensities from triplicate wells.
Background signal was subtracted.
Statistical analysis
Results were expressed as Means ± S.E. One-way ANOVAs
followed by Turkey’s multiple comparisons test were used to
detect significant differences among treatments. Statistical
analyses were performed with STATISTICA 6.0 (StatSoft, Inc.).
Differences were regarded as significant at p<0.05.
Results
Analysis of cell morphology, stem cell markers
expression and karyotype in Mycoplasma sp. infected
human embryonic stem cells cured with PlasmocinTM
antibiotic
A stable HUES-5 (H5) hESC line encoding GFP gene under
the control of a fragment of the Brachyury promoter (H5 884)
was developed for mesoderm-based studies. Unfortunately,
after months of work and before being cryopreserved (initial
stock), Mycoplasma sp. contamination was detected in this cell
line by PCR analysis (Figure 1A, lane 4). As this culture was
considered an extremely valuable tool, we decided to try to
eradicate Mycoplasma sp. contamination. For this purpose, H5
884 cells were treated with Plasmocin 25 µg/ml during 14
consecutive days (curative treatment). As shown in Figure 1A,
after 7 days antibiotic treatment (lane 2), positive PCR band
decreased. Moreover, after 14 days treatment (lane 3),
Mycoplasma sp. genomic DNA was not amplified. Importantly,
6 months post-PlasmocinTM curative treatment Mycoplasma sp.
continued undetected on H5 884 cells, which means that cells
remained free of mycoplasmas over long-term culturing (Figure
1A, lane 7). These results indicate that we were able to
permanently eradicate Mycoplasma sp. infection from H5 884
cells.
We next tested if PlasmocinTM curative treatment affected
undifferentiated status, self-renewal and karyotype of H5 884
hESCs. After antibiotic curative treatment, H5 884 cells
morphology was compared to H5 cells. As it can be seen in
Figure 1B, H5 884 cells retained hESCs morphological
characteristics, like formation of compact multicellular colonies
with a high nucleus/cytoplasm ratio, prominent nucleoli and
distinct colony borders.
Furthermore, H5 and cured H5 884 cells were grown until
confluence on MatrigelTM coated culture dishes and then stem
cells associated markers expression was analyzed by
immunofluorescence microscopy. Both H5 and H5 884 cells
exhibited robust expression of different stemness markers,
such as the nuclear located transcription factors Oct-4 and
Nanog and the surface markers SSEA-4, TRA1-60 and
TRA1-81. No areas of lack of expression of stemness markers
were detected (Figure 1C). Moreover, tested cell lines also
expressed significant high levels of stemness associated
transcripts, quantified by RT-Real time PCR, such as oct-4 and
nanog, compared to human fibroblasts (Figure 1D). Besides,
no significant difference was observed between H5 884 and H5
cells.
As previously mentioned, both Mycoplasma sp.
contamination and antibiotic treatment may cause
chromosomal abnormalities. Interestingly, after mycoplasmas
eradication treatment, H5 884 cells exhibited the same
karyotype [46,XX, inv(9) (p12q13)] (Figure 1E) as the parental
H5 line [24].
All together, the above results show that PlasmocinTM
curative anti-Mycoplasma sp. treatment did not affect hESCs
undifferentiated state nor karyotype.
Effect of PlasmocinTM anti-Mycoplasma sp. curative
treatment on human embryonic stem cells pluripotency
Based on our observation that Mycoplasma sp. infected
hESCs cured with PlasmocinTM antibiotic retained their
stemness, we asked if this curative treatment affected hESCs
Effect of Anti-Mycoplasma Antibiotics on hESCs
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Figure 1.  Infected hESCs cured with PlasmocinTM maintain their morphology, stem cell markers expression and
karyotype.  Mycoplasma sp. infected HUES-5 884 (H5 884) cells were treated with Plasmocin 25 µg/ml during 14 days (Curative
treatment) and: (A) Mycoplasma sp. infection was followed by genomic DNA PCR analysis at day 0, 7 and 14 after antibiotic
addition (lanes 4, 2 and 3), in non infected parental H5 line (lane 1) and in cured cells after 6 month post-treatment (lane 7) Control
+: Mycoplasma orale genomic DNA (lanes 5 and 9). Control -: H2O (lanes 6 and 8); (B) Cured H5 884 cells were photographed
using an inverted microscope in order to compare to HUES-5 (H5) colony morphology. Figure shows representative bright field
photomicrographs. Scale bars = 100 µm; (C) H5 and cured H5 884 cells were grown on MatrigelTM coated plates until confluence
and stained with primary antibodies that recognize stem cell markers. Figure shows representative fluorescent photomicrographs of
hESCs immunostained with SSEA-4, TRA-1-60, TRA-1-81, Nanog and Oct-4. Scale bars = 100 µm; (D) H5 884 mRNA levels of
oct-4 and nanog were analyzed by RT-Real Time PCR after 14 days of curative treatment and compared to H5 levels. Rpl7
expression was used as normalizer. Graph shows mRNA fold induction relative to human fibroblasts (HF). The mean ± S.E. from
three independent experiments are shown. * = p<0.05; (E) Karyotype analysis of cured H5 884 cells. A representative GTG-banded
metaphase spread is shown. Abbreviations: SSEA-4, Stage-Specific Embryonic Antigen; TRA-1-60, Tumor Rejection Antigen 1-60;
TRA-1-81, Tumor Rejection Antigen 1-81; Oct-4, Octamer 4.
doi: 10.1371/journal.pone.0070267.g001
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pluripotent potential. In vitro differentiation of hESCs can be
achieved by removing cells from feeders layers and growing
them in suspension (with the addition of serum which contains
all necessary differentiation signals) on a non-adherent surface
[26]. Under these conditions, pluripotent hESCs form three-
dimensional multicellular aggregates called embryoid bodies
(EBs) and differentiate into any cell lineage of the three germ
layers. Importantly, cured H5 884 cells responded to the
differentiation protocol in a similar way to H5 cells. In this
sense, mRNA levels of oct-4 and nanog, diminished at days 4,
7 and 14 of the onset of differentiation (Figure 2A). At the same
time points, mRNA levels of differentiation markers, such as
pax-6 (ectoderm), brachyury (early mesoderm), nkx2.5 (cardiac
mesoderm) and α-fetoprotein (endoderm), were up-regulated
(Figure 2A). Moreover, on day 14 of the differentiation protocol
(after 7 days in suspension followed by 7 days of outgrowth in
gelatin coated-dishes) we observed formation of neuro-
ectoderm, endoderm and cardiac contractile regions, positively
stained for Nestin, α-Fetoprotein (AFP) and cardiac Troponin T
(cTnT), respectively (Figure 2B).
As previously mentioned, stable H5 884 cell line encodes
GFP gene under the control of a fragment of the Brachyury
promoter. Brachyury is an early mesoderm marker whose
expression peaks at day 4 of the EBs-based differentiation
protocol. We were able to detect GFP green fluorescence
(indicative of Brachyury promoter up-regulation) in some H5
884 EBs at day 4 of the onset of differentiation (Figure 2C).
These observations confirmed that PlasmocinTM curative
treatment did not impair hESCs pluripotent potential.
Impact of Ciprofloxacin anti-Mycoplasma sp. "curative"
treatment on human embryonic stem cells cell
morphology, stem cells markers expression and
pluripotency.  H5 cells were treated with Ciprofloxacin 10
µg/ml during 14 days in order to mimic a curative treatment.
After antibiotic treatment, cells retained hESCs morphological
characteristics compared to control untreated cells (Figure 3A).
After Ciprofloxacin "curative" treatment, H5 stem cells
associated markers expression was analyzed by RT-Real Time
PCR and immunofluorescence microscopy. As occurred with
PlasmocinTM curative treatment, Ciprofloxacin-treated and
untreated cells robustly express stemness markers at both
mRNA and protein levels (Figure 3C).
Maintenance of H5 pluripotent potential after Ciprofloxacin
"curative" treatment was then tested. Importantly, treated H5
hESCs responded to the EBs differentiation protocol in a
similar way to untreated cells. Again, mRNA levels of oct-4 and
nanog, quantified by RT-Real time PCR, diminished at days 4,
7 and 14 of the onset of differentiation (Figure 3D). At the same
time points, mRNA levels of pax-6, brachyury, nkx2.5 and α-
fetoprotein were up-regulated (Figure 3D). Moreover, on day
14 of the differentiation regions of Nestin, AFP or cTnT-positive
cells were identified by immunocytochemistry (Figure 3E). All
together, the above results show that Ciprofloxacin anti-
Mycoplasma sp. "curative" treatment did not affect hESCs
undifferentiated state nor pluripotency.
PlasmocinTM prophylactic anti-Mycoplasma sp.
treatment: implications on human embryonic stem cells
special characteristics
hESC lines H9 and H5 were treated with PlasmocinTM 5
µg/ml during 5 consecutive passages (prophylactic treatment).
Importantly, post-prophylactic treatment cells retained hESCs
morphological characteristics and stem cells associated
markers expression (analyzed by RT-Real Time PCR and
immunofluorescence) compared to control untreated cells
(Figure 4A and B). Moreover, H9 and H5 treated and control
untreated cells exhibited robust expression of Oct-4, Nanog,
SSEA-4, TRA1-60 and TRA1-81 (Figure 4A). Besides, oct-4
and nanog transcripts were significantly highly expressed in H9
and H5 treated cells compared to human fibroblasts (Figure
4B). Despite the expected variability observed between
different passages, no significant differences in either oct-4 or
nanog expression was observed between treated (prophylactic)
and control cells (Figure 4B).
We next wondered if PlasmocinTM prophylactic treatment
affects H9 and H5 hESCs pluripotent potential. Treated and
control hESCs H5 and H9 were differentiated using the EBs
differentiation protocol. Once again, H5 and H9 hESCs
responded equally to the EBs differentiation protocol as judged
by RT-Real time PCR analysis of stemness and differentiation
markers mRNAs levels and immunofluorescence microscopy
with antibodies against Nestin, AFP and cTnT (Figure 5A and
B). We can conclude from these experiments that PlasmocinTM
prophylactic treatment against Mycoplasma sp. infection did
not altered hESCs special characteristics, like stemness
properties and pluripotency.
Cytotoxicity of PlasmocinTM and Ciprofloxacin
antibiotics on hESCs viability, apoptosis rate and
growth
As previously mentioned, anti-Mycoplasma sp. antibiotics
could have cytotoxic effects on cell viability. We next evaluated
if PlasmocinTM at 5 and 25 µg/ml and Ciprofloxacin at 10 µg/ml
could affect cell viability of confluent H5 and H9 hESCs grown
in feeder-free conditions. As shown in Figure 6A, after 24 and 7
days treatments, the percentage of viable cells did not
significantly change. Importantly, neither PlasmocinTM nor
Ciprofloxacin at the concentrations tested decreased hESCs
viability.
Chromatin condensation paralleled by DNA fragmentation
are two of the most important criteria which are used to identify
apoptotic cells. Therefore we next measured these processes
after 7 days of PlasmocinTM (5 or 25 µg/ml) or Ciprofloxacin (10
µg/ml) treatments on H5 and H9 cells by DAPI staining of
nuclear DNA and TUNEL technique, respectively. We found
that antibiotics treatment did not significantly increased the
percentage of hESCs DAPI positive apoptotic nuclei (Figure
6B). Moreover, in what it concerns to DNA fragmentation, no
significant increase in TUNEL-positive cells was found in H5
and H9 hESCs treated cells (Figure 6C). In conclusion,
PlasmocinTM and Ciprofloxacin treatments did not affect hESCs
apoptosis rate.
Finally, we studied if antibiotic treatments affect hESCs
growth. In order to answer this question, we plated small
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clusters of H9 cells on iMEF feeder layers and, after 7 days of
PlasmocinTM (5 and 25 µg/ml) and Ciprofloxacin (10 µg/ml)
treatments, hESCs colonies size and number were analyzed.
Qualitative observation of alkaline phosphatase staining
(phenotypic marker of pluripotent stem cells) of H9 cells
showed smaller colony size for antibiotic treated cells, with
PlasmocinTM 25 µg/ml and Ciprofloxacin 10 µg/ml, compared to
control cells. However, total colony number remained unaltered
(Figure 7A). Moreover, In-Cell Western analysis of H9 cells
revealed significant lower fluorescent signals for Nanog and
Oct-4 on PlasmocinTM 25 µg/ml and Ciprofloxacin 10 µg/ml 7
days-treated cells (Oct-4: 0.69±0.09, 0.70±0.08; Nanog:
0.64±0.09, 0.51±0.15 fluorescence intensity fold change vs.
control untreated cells, for PlasmocinTM 25 µg/ml and
Figure 2.  Differentiation of hESCs cured with PlasmocinTM.  H5 884 cells treated with PlasmocinTM 25 µg/ml during 14 days
(Curative treatment) and H5 cells were differentiated using the EBs protocol and then: (A) mRNA levels of oct-4 and nanog,
ectoderm (pax-6), mesoderm (brachyury and nkx2.5) and endoderm (α-fetoprotein) markers were analyzed by RT-Real Time PCR
at days 0, 4, 7 and 14 of the differentiation protocol. Rpl7 expression was used as normalizer. Graph shows mRNA fold induction
relative to day 0. The mean ± S.E. from three independent experiments are shown. (B) Cells were grown on gelatin coated plates
from day 7 to 14 of differentiation and then ectoderm (neural rosettes), cardiac mesoderm (contractile EBs) and endoderm
structures were stained with primary antibodies that recognize Nestin (ectoderm), cTnT (cardiac mesoderm) and AFP (endoderm)
markers. Figure shows representative images. Scale bars = 100 µm. (C) Cured H5 884 cells, which express GFP gene under the
control of the Brachyury promoter, were differentiated using the EBs protocol. At day 4 of the onset of differentiation GFP green
fluorescence was photographed using an inverted fluorescence microscope. Figure shows representative images. Arrows indicate
GFP positive regions or EBs. Scale bars = 100 µm. Abbreviations: BF, Bright field; Pax-6, Pair box protein 6; Nkx2.5, NK2
homeobox 5; cTnT, Cardiac troponin T; AFP, Alpha-fetoprotein; GFP, Green fluorescent protein.
doi: 10.1371/journal.pone.0070267.g002
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Figure 3.  hESCs treated with Ciprofloxacin maintain their morphology, stem cell markers expression and pluripotency.  H5
cells were treated with Ciprofloxacin 10 µg/ml during 14 days (Curative treatment mimic) and then: (A) photographed using an
inverted microscope in order to compare colony morphology. Control: untreated cells. Figure shows representative bright field
photomicrographs. Scale bars = 100 µm; (B) mRNA levels of the stemness markers oct-4 and nanog were analyzed by RT-Real
Time PCR after 14 days of "curative" treatment. Rpl7 expression was used as normalizer. Control: untreated cells. Graph shows
mRNA fold induction relative to human fibroblasts (HF). The mean ± S.E. from three independent experiments are shown. * =
p<0.05; (C) cells were grown on MatrigelTM coated plates until confluence and stained with primary antibodies that recognize stem
cell markers. Control: untreated cells. Figure shows representative fluorescent photomicrographs of hESCs immunostained with
SSEA-4, TRA-1-60, TRA-1-81, Nanog and Oct-4. Scale bars = 100 µm; (D) mRNA levels of stemness (oct-4 and nanog), ectoderm
(pax-6), mesoderm (brachyury and nkx2.5) and endoderm (α-fetoprotein) markers were analyzed by RT-Real Time PCR at days 0,
4, 7 and 14 of the EBs differentiation protocol. Rpl7 expression was used as normalizer. Control: untreated cells. Graph shows
mRNA fold induction relative to day 0. The mean ± S.E. from three independent experiments are shown. (E) Cells were grown on
gelatin coated plates from day 7 to 14 of differentiation and then ectoderm (neural rosettes), cardiac mesoderm (contractile EBs)
and endoderm structures were stained with primary antibodies that recognize Nestin (ectoderm), cTnT (cardiac mesoderm) and
AFP (endoderm) markers. Figure shows representative images. Scale bars = 100 µm.
doi: 10.1371/journal.pone.0070267.g003
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Figure 4.  hESCs maintain their morphology and stem cell markers expression upon PlasmocinTM prophylactic
treatment.  WA09 (H9) and H5 cells were treated with PlasmocinTM 5 µg/ml during 5 consecutive passages (one passage per week)
(Prophylactic treatment) and then: (A) photographed using an inverted microscope in order to compare colony morphology; and
grown on MatrigelTM coated plates until confluence and stained with primary antibodies that recognize stem cell markers. Control:
untreated cells. Figure shows representative bright field and fluorescent images of hESCs immunostained or not with antibodies
against SSEA-4, TRA-1-60, TRA-1-81, Nanog and Oct-4. Scale bars = 100 µm; (B) mRNA levels of oct-4 and nanog were analyzed
by RT-Real Time PCR on each passage of the 5 consecutive passages of the prophylactic treatment. Control: untreated cells. Rpl7
expression was used as normalizer. Graph shows mRNA fold induction relative to human fibroblasts (HF). The mean ± S.E. from
three independent experiments are shown. *=p<0.05.
doi: 10.1371/journal.pone.0070267.g004
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Figure 5.  Differentiation of hESCs upon PlasmocinTM prophylactic treatment.  H5 and H9 cells treated with PlasmocinTM 5
µg/ml during 5 consecutive passages (Prophylactic treatment) were differentiated using the EBs protocol and then: (A) mRNA levels
of stemness (oct-4 and nanog), ectoderm (pax-6), mesoderm (brachyury and nkx2.5) and endoderm (α-fetoprotein) markers were
analyzed by RT-Real Time PCR at days 0, 4, 7 and 14 of the differentiation protocol. Rpl7 expression was used as normalizer.
Control: untreated cells. Graph shows mRNA fold induction relative to day 0. The mean ± S.E. from three independent experiments
are shown. (B) Cells were grown on gelatin coated plates from day 7 to 14 of differentiation and then ectoderm (neural rosettes),
cardiac mesoderm (contractile EBs) and endoderm structures were stained with primary antibodies that recognize Nestin
(ectoderm), cTnT (cardiac mesoderm) and AFP (endoderm) markers. Control: untreated cells. Figure shows representative images.
Scale bars = 100 µm.
doi: 10.1371/journal.pone.0070267.g005
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Figure 6.  Cell viability and apoptosis rate of hESCs treated with PlasmocinTM and Ciprofloxacin.  (A) Cell viability was
assessed by XTT colorimetric assay performed at 24 h and 7 days post PlasmocinTM (5 or 25 µg/ml) or Ciprofloxacin (10 µg/ml)
treatments on feeder-free confluent H5 and H9 cells. The results are presented as percentage of control untreated cells. Bars
indicate mean ± S.E. of four replicates from three independent experiments (n=12). * = p< 0.05. (B) Chromatin condensation was
analyzed by DAPI staining of H5 and H9 cells grown on iMEF feeder layer and treated with PlasmocinTM (5 or 25 µg/ml) or
Ciprofloxacin (10 µg/ml) for 7 days. Figure shows representative images and arrows indicate apoptotic nuclei. Mean ± S.E. from
three independent experiments are graphed for % of apoptotic nuclei. Scale bars = 100 µm. * = p<0.05. (C) DNA fragmentation was
assessed by TUNEL assay performed at 7 days post PlasmocinTM (5 or 25 µg/ml) or Ciprofloxacin (10 µg/ml) treatments on H5 and
H9 cells grown on iMEF feeder layer and is expressed as percentage of TUNEL positive nuclei. Control: untreated cells. Positive
control: control cells treated with DNAse I. Negative control: control cells in label solution only (without terminal transferase).
Representative images are shown and arrows indicate TUNEL positive nuclei. Mean ± S.E. from three independent experiments are
graphed. Scale bars = 100 µm. *=p<0.05.
doi: 10.1371/journal.pone.0070267.g006
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Ciprofloxacin 10 µg/ml, respectively) (Figure 7B). This
quantification perfectly correlates with the smaller colony size
observed (Figure 7B). Importantly, after antibiotics withdrawal
cell growth rate was recovered (Figure 7C).
Taken together, these results indicate that the anti-
Mycoplasma sp. antibiotics tested herein did not affect cell
viability or apoptosis rate. Nevertheless, Ciprofloxacin and
PlasmocinTM at curative concentrations (10 and 25 µg/ml,
respectively) diminished cell growth.
Discussion
hESCs cell therapies have been proposed for regenerative
medicine and tissue replacement after injury or disease [1].
Besides these promising uses, hESCs are currently useful
tools for early human development basic research, genetic
disease modeling and in vitro systems for toxicology testing
[27].
However, hESCs may harbor infectious agents, particularly
Mycoplasma sp., acquired during in vitro culture. The use of
contaminated differentiated cells for cell replacement therapies
increases the risk of transmitting infectious agents to human
patients. In addition, alteration of host cellular characteristics
caused by contaminating Mycoplasma sp., can greatly
influence the experimental results obtained with hESCs on
research and in vitro toxicity test models and, therefore lead to
misleading conclusions. Moreover, contamination can also
result in economic setbacks because of the loss of time and,
since mycoplasmas are hard to eradicate, the loss of precious
cell lines. Taken these drawbacks into account, it is essential to
extreme aseptic conditions and to emphasize the need to
regularly screen cell cultures for mycoplasmal contamination.
There are many different methods for the detection of
Mycoplasma sp. contamination in cell cultures, as for example
microbial culture expansion in broth culture and detection by
colony formation on nutrient agar plates, DNA fluorochrome
staining and biochemical assays [28]. However, infections can
remain undetected unless more sensitive methods such as
polymerase chain reaction (PCR) are employed. MEFs and
hESCs lines cultured in this work were routinely tested for
Mycoplasma sp. contamination by PCR, using Mycoplasma
sp.-specific primer sequences [29]. Except for the infected H5
884 cells, in all cases cultures resulted free of contaminants.
Laboratory personnel, contaminated serum or reagents and
other contaminated cell cultures are the major sources of
Mycoplasma sp. infections [12,14,30]. Thus, positive cultures
should be discarded and replaced in order to prevent the
spreading of the contaminant. If the culture is considered
irreplaceable, like recently generated hESC stable lines (our
H5 884 hESC line for example) or induced pluripotent stem cell
lines, it is possible to effectively eliminate the Mycoplasma sp.
contamination. Obviously, methods of mycoplasmas
eradication should be simple, have minimal effect on cell
growth and not lead to loss of special cellular hESCs
characteristics. The most simple and effective technique is
antibiotic treatment and many different anti-Mycoplasma sp.
reagents, including PlasmocinTM and Ciprofloxacin, have been
already used successfully in several different eukaryotic cell
lines [12,14–16,21]. Nevertheless, changes in culture
conditions of hESCs could lead to the loss of the ability of self-
renewal, pluripotency and induction of differentiation. In this
sense, understanding if anti-Mycoplasma sp. antibiotics could
cure Mycoplasma sp.-infected hESCs, how they could affect
these special properties and also if they exert cytotoxic effects
over hESCs viability and growth is of growing interest in the
search of better ways of controlling Mycoplasma sp. infections
in hESCs culture facilities.
In the present study, we assessed for the first time the effect
of the anti-Mycoplasma sp. antibiotics PlasmocinTM and
Ciprofloxacin on hESCs stemness, pluripotency, cell viability
and growth. We used three different approaches: first, a 14-
days curative treatment course with high concentrations of
PlasmocinTM (25 µg/ml) in order to cure hESCs (H5 884)
infected with mycoplasmas; second, a 14-days treatment
course with high concentrations of Ciprofloxacin (10 µg/ml) that
mimics a treatment that could be used to eradicate
Mycoplasma sp. infections ("curative" treatment); third,
treatment with PlasmocinTM at a concentration of 5 µg/ml during
5 consecutive passages in order to test if this antibiotic could
be used to prevent from Mycoplasma sp. contamination
(prophylactic treatment). After treatments, antibiotics were
withdrawn and we tested if cells continued satisfying the criteria
used to define a pluripotent state. We found that the expression
profile of stemness markers and morphological characteristics
in antibiotic prophylactic and curative-treated cells did not differ
from control untreated or parental cells. Besides, karyotype of
PlasmocinTM-cured H5 884 was still the same of H5 parental
cells. Moreover, we were able to identify cell derivatives of the
three embryonic germ layers in EBs derived from hESCs
treated with PlasmocinTM or Ciprofloxacin under both curative
and prophylactic conditions.
The above results indicate that these cells are still pluripotent
and though are capable to differentiate in vitro. Thus,
PlasmocinTM and Ciprofloxacin curative and prophylactic
treatments did not affect hESCs differentiation characteristics
and could be used to eradicate and prevent Mycoplasma sp.
contamination on these cells. However, application of
antibiotics in cell culture should be limited, as indiscriminate
use could lead, among others, to the emergence of resistant
mycoplasmas strains. To lessen this effect PlasmocinTM
contains two bactericidal components strongly active against
mycoplasmas. The first component acts on the protein
synthesis machinery while the second acts on the DNA
replication. The combination of these two not related
bactericidal components makes highly unlikely the appearance
of resistant Mycoplasma sp. In contrast, Ciprofloxacin is a
quinolone that only inhibits topoisomerase enzymes (relaxation
of supercoiled DNA is affected promoting breakage of double
stranded DNA), so prolonged use of this antibiotic on cell
culture may lead to the selection of resistant mycoplasmas.
Anti-Mycoplasma sp. antibiotics could have cytotoxic effects
over hESCs viability and growth. We found that neither
PlasmocinTM nor Ciprofloxacin at the concentrations studied
affected H9 and H5 hESCs viability or apoptosis rate. In this
sense, previous studies on Mycoplasma sp. free eukaryotic cell
lines do not provide any evidence of antibiotic effect on host
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Figure 7.  Cell growth of hESCs treated with PlasmocinTM and Ciprofloxacin.  (A) Alkaline phosphatase staining of H9 cells
grown on iMEF feeder layer after 7 days of treatment with PlasmocinTM (5 or 25 µg/ml) or Ciprofloxacin (10 µg/ml). Control:
untreated cells. Representative images and 250% magnifications are shown. Colony number is graphed. Bars indicate mean ± S.E.
of three independent experiments. * = p<0.05. (B) In-Cell Western analysis of Nanog and Oct-4 stemness markers on H9 cells
grown on iMEF feeder layer after 7 days of treatment with PlasmocinTM (5 or 25 µg/ml) or Ciprofloxacin (10 µg/ml). Control:
untreated cells. Representative images are shown. Fluorescence intensity fold induction vs. Control is shown. Bars indicate mean ±
S.E. of three independent experiments. * = p<0.05. (C) After 14 days PlasmocinTM (25 µg/ml) or Ciprofloxacin (10 µg/ml) "curative"
treatments, antibiotics were removed and H9 cells were passaged twice and then grown on iMEF feeder layer for 7 days under
regular culture media conditions in order to study Nanog and Oct-4 stemness markers expression by In-Cell Western. Control:
untreated cells. Representative images are shown. Fluorescence intensity fold induction vs. Control is shown. Bars indicate mean ±
S.E. of three independent experiments. *=p<0.05.
doi: 10.1371/journal.pone.0070267.g007
Effect of Anti-Mycoplasma Antibiotics on hESCs
PLOS ONE | www.plosone.org 13 July 2013 | Volume 8 | Issue 7 | e70267
cell viability toxicity [31]. However, we observed that
PlasmocinTM and Ciprofloxacin at curative concentrations (25
and 10 µg/ml, respectively) significantly reduced H9 hESCs
growth rate. Importantly, this effect was reversible, as growth
rate was recovered after antibiotic withdrawal. On the other
hand, the effect of PlasmocinTM on cell growth rate at
prophylactic concentrations (5 µg/ml) was minimum. Previous
reports described inhibitory effects of Ciprofloxacin on
hematopoietic progenitors cell growth [32,33]. Moreover, at
high concentrations of PlasmocinTM (like 25 µg/ml), slowdown
of cell growth had been already observed. This slowing down
was mainly due to the inhibition of mitochondrial respiration by
PlasmocinTM (manufacturer information).
In conclusion, PlasmocinTM and Ciprofloxacin anti-
Mycoplasma sp. antibiotics, at both curative and prophylactic
treatment conditions, did not affect cell viability, maintenance of
the undifferentiated state and pluripotency of hESCs. Proper
cell culture aseptic practices along with specific, sensitive and
reliable detection methods can provide an appropriate situation
to prevent Mycoplasma sp. contamination in hESCs culture
facilities. However, according to our findings, if an irreplaceable
hESCs culture is contaminated, either of these antibiotics could
be used to eradicate mycoplasmas. Moreover, PlasmocinTM at
prophylactic concentrations could be used, preferably during
short periods of time, to prevent from Mycoplasma sp.
contaminations in high-risk environments. Nevertheless, further
experiments using define differentiation protocols should be
perform to discard the possibility that lineage-restricted
progenitors or terminally differentiated cell populations could be
affected.
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